Myeloma Panel by FCM/Bone Marrow
This panel uses flow cytometry (FCM) to detect genetic abnormalities in bone marrow cells in multiple myeloma. It assists in diagnosing the disease and predicting patient outcomes.
Myeloma Panel by FCM/Bone Marrow Package in Karnal Overview
What is Myeloma panel by flowcytometry test?
Myeloma panel by flowcytometry test is a multi‑color flow cytometry panel that uses antibodies against plasma cell and B‑cell markers (e.g., CD38, CD138, CD45, CD19, CD56, CD27, CD117, Kappa, and Lambda) to identify abnormal clonal plasma cells and separate them from normal counterparts. This comprehensive panel aids healthcare professionals in accurate disease detection, classification, and treatment planning for patients with multiple myeloma.
Why consider Myeloma panel by flowcytometry test?
Myeloma panel by flowcytometry test is considered for diagnosing multiple myeloma (MM), differentiating it from other conditions, determining its staging and prognosis, and monitoring the effectiveness of treatment, as it precisely identifies and quantifies abnormal plasma cells in the bone marrow and blood. This test is crucial because it provides detailed information about plasma cell characteristics, such as their surface protein expression, which helps distinguish neoplastic cells from normal ones and assesses their risk of progression.
- Diagnosing multiple myeloma
- Differentiating from other conditions
- Staging and prognosis
- Monitoring treatment
- Identifying circulating tumor cells
Who should get tested for Myeloma panel by flowcytometry test?
- Individuals with suspected or established multiple myeloma, smoldering myeloma, or related plasma cell dyscrasias undergoing diagnostic workup or response monitoring.
- Patients post‑treatment where sensitive detection of residual clonal plasma cells can guide prognosis and therapeutic decisions.
More Information about Myeloma panel by flowcytometry test
Multiple Myeloma (MM) belongs to a family of neoplasms involving clonal expansion of immunoglobulin secreting B-cells, often with bone marrow involvement, resulting in anemia and leukopenia. Additionally, bone lesions are often seen. This FISH panel is designed to detect the most common, and/or prognostically-significant abnormalities in Multiple Myeloma and related plasma cell neoplasms. Multiple myeloma arises from clonal plasma cells that accumulate in bone marrow and produce a monoclonal immunoglobulin (M-protein) or free light chains that can harm organs.
Other Names: Multiple Myeloma Flow Cytometry Panel; Plasma Cell Immunophenotyping by Flow Cytometry; Multiple myeloma diagnostic test
No special preparations needed
- Cd19
- Cd20
- Cd38
- Cd45
- Cd56
- Kappa
- Lambda
- Kappa/lambda Ratio
- Cd117
- Cd138
- Instrument/software Used
- Cell Preparation Method
- Gating Strategy
- Specimen Type
- Wbc Count
- Plasma Cells
Test code
1607
Specimen vol. and vacutainer information
| Specimen | Vacutainer | Volume |
|---|---|---|
| Bone Marrow | Others | 11 ML |
| Edta Whole Blood | Lavender Vacutainer | 12 ML |
| Heparin Whole Blood | Green Vacutainer | 12 ML |
| Smear | Others | 11 NOS |
Specimen stability information
Bone Marrow, Edta Whole Blood, Heparin Whole Blood, Smear
Collection instructions
2-3 unfixed, unstained direct smears + Detailed Clinical history medatory, Fluid send in RPMI 1:1 in plain container
Specimen rejection criteria
Test run frequency
'
Turn around time
Next Day
Performing locations
Department
- Flow Cytometry
CPT and Loinc codes
Package price
₹7500
Need Help?
Talk to our health experts for guidance on tests, reports, or bookings.
WhatsApp to Book TestMyeloma Panel by FCM/Bone Marrow
₹7500